MAGNETIC-RESONANCE-IMAGING EVIDENCE OF DECREASED PUTAMENAL IRON CONTENT IN IDIOPATHIC PARKINSONS-DISEASE

被引:73
作者
RYVLIN, P
BROUSSOLLE, E
PIOLLET, H
VIALLET, F
KHALFALLAH, Y
CHAZOT, G
机构
[1] HOP NEUROL,DEPT NEUROL,SERV NEUROL,F-69003 LYON,FRANCE
[2] FAC MED ALEXIS CARREL,INSERM,U197,EXPTL MED LAB,F-69372 LYON,FRANCE
[3] CLIN STE CATHERINE,DEPT MAGNET RESONANCE IMAGING,AVIGNON,FRANCE
[4] CTR HOSP GEN,DEPT NEUROL,AIX EN PROVENCE,FRANCE
关键词
D O I
10.1001/archneur.1995.00540300057013
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To determine the changes in basal ganglia iron content associated with various stages of idiopathic Parkinson's disease. Design: Prospective magnetic resonance imaging study using a 2-T magnet. Setting: Ambulatory care referral center. Patients and Participants: Forty-five patients suffering from levodopa-responsive Parkinson's disease and 45 age-matched controls. Main Outcome Measures: The T-2 relaxation time calculated in various regions of the basal ganglia, the duration of Parkinson's disease, and the age of subjects. Results: Patients with Parkinson's disease exhibited significantly decreased T-2 relaxation time in the pars compacta of the substantia nigra compared with controls (P<.01), regardless of disease duration. Patients with a duration of illness above 10 years (n=12) exhibited significantly increased T-2 relaxation time in the anterior and posterior putamen (P<.005 and P<.01, respectively) and in the pallidum (P<.05) compared with age-matched controls. Putamenal T-2 relaxation time positively correlated with disease duration (P<.05). Conclusion: These results suggest that more complex brain iron changes than those previously reported are associated with idiopathic Parkinson's disease, including increased nigral iron content and decreased putamenal and pallidal iron concentration in patients with a duration of illness above 10 years.
引用
收藏
页码:583 / 588
页数:6
相关论文
共 46 条
[1]   T2 RELAXATION-TIME IN PATIENTS WITH PARKINSONS-DISEASE [J].
ANTONINI, A ;
LEENDERS, KL ;
MEIER, D ;
OERTEL, WH ;
BOESIGER, P ;
ANLIKER, M .
NEUROLOGY, 1993, 43 (04) :697-700
[2]   THE IRON CHELATOR DESFERRIOXAMINE (DESFERAL) RETARDS 6-HYDROXYDOPAMINE-INDUCED DEGENERATION OF NIGROSTRIATAL DOPAMINE NEURONS [J].
BENSHACHAR, D ;
ESHEL, G ;
FINBERG, JPM ;
YOUDIM, MBH .
JOURNAL OF NEUROCHEMISTRY, 1991, 56 (04) :1441-1444
[3]   IRON MELANIN INTERACTION AND LIPID-PEROXIDATION - IMPLICATIONS FOR PARKINSONS-DISEASE [J].
BENSHACHAR, D ;
RIEDERER, P ;
YOUDIM, MBH .
JOURNAL OF NEUROCHEMISTRY, 1991, 57 (05) :1609-1614
[4]   INTRANIGRAL IRON INJECTION INDUCES BEHAVIORAL AND BIOCHEMICAL PARKINSONISM IN RATS [J].
BENSHACHAR, D ;
YOUDIM, MBH .
JOURNAL OF NEUROCHEMISTRY, 1991, 57 (06) :2133-2135
[5]   ROLE OF IRON AND FERRITIN IN MR IMAGING OF THE BRAIN - A STUDY IN PRIMATES AT DIFFERENT FIELD STRENGTHS [J].
BIZZI, A ;
BROOKS, RA ;
BRUNETTI, A ;
HILL, JM ;
ALGER, JR ;
MILETICH, RS ;
FRANCAVILLA, TL ;
DICHIRO, G .
RADIOLOGY, 1990, 177 (01) :59-65
[6]  
BRAFFMAN BH, 1988, AM J NEURORADIOL, V9, P1093
[7]   DOES SIGNAL-ATTENUATION ON HIGH-FIELD T2-WEIGHTED MRI OF THE BRAIN REFLECT REGIONAL CEREBRAL IRON DEPOSITION - OBSERVATIONS ON THE RELATIONSHIP BETWEEN REGIONAL CEREBRAL WATER PROTON T2 VALUES AND IRON LEVELS [J].
BROOKS, DJ ;
LUTHERT, P ;
GADIAN, D ;
MARSDEN, CD .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1989, 52 (01) :108-111
[8]   T2 VALUES IN THE HUMAN-BRAIN - COMPARISON WITH QUANTITATIVE ASSAYS OF IRON AND FERRITIN [J].
CHEN, JC ;
HARDY, PA ;
CLAUBERG, M ;
JOSHI, JG ;
PARRAVANO, J ;
DECK, JHN ;
HENKELMAN, RM ;
BECKER, LE ;
KUCHARCZYK, W .
RADIOLOGY, 1989, 173 (02) :521-526
[9]  
DEXTER D, 1987, LANCET, V8569, P1219
[10]   DECREASED FERRITIN LEVELS IN BRAIN IN PARKINSONS-DISEASE [J].
DEXTER, DT ;
CARAYON, A ;
VIDAILHET, M ;
RUBERG, M ;
AGID, F ;
AGID, Y ;
LEES, AJ ;
WELLS, FR ;
JENNER, P ;
MARSDEN, CD .
JOURNAL OF NEUROCHEMISTRY, 1990, 55 (01) :16-20